caption
stringlengths 6
2.51k
| molecule
stringlengths 1
747
| properties
sequencelengths 1
86
|
|---|---|---|
The molecule is a energy storage, a emulsifier, a stabilizing cytochrome oxidase, and smooth. The molecule is a cholesterol translocation and a stabilizing mitochondrial structure that impacts diabetic heart disease, tangier disease, and non-alcoholic fatty liver disease. The molecule is a apoptosis, a energy source, and a membrane stabilizer, and it impacts aging. The molecule is a surfactant, food additive, nutritional supplement, proton trap for oxidative phosphorylation that impacts barth syndrome. | CCC(C)CCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)CC | [
"Energy storage",
"Smooth",
"Emulsifier",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Aging",
"Energy source",
"Membrane stabilizer",
"surfactant",
"food additive",
"Barth syndrome",
"Nutritional supplement",
"Proton trap for oxidative phosphorylation"
] |
The molecule is a membrane stabilizer and a nutrient, belonging to the anti oxidant class of molecules. The molecule is a energy storage, surfactant, emulsifier, energy source. | CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(\C)CCC2=C(C)CC(O)CC2(C)C)C(C)(C)CC(O)C1 | [
"Membrane stabilizer",
"anti oxidant",
"nutrient",
"Energy storage",
"surfactant",
"Emulsifier",
"Energy source"
] |
The molecule is a energy storage, a membrane stabilizer, and a energy source, and it impacts non-alcoholic fatty liver disease. The molecule is a food additive, nutritional supplement, emulsifier that impacts diabetic heart disease and aging. The molecule is a apoptosis, proton trap for oxidative phosphorylation, cholesterol translocation, stabilizing mitochondrial structure. The molecule is a stabilizing cytochrome oxidase and a surfactant, which impacts both tangier disease and barth syndrome, and is characterized as smooth. | CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Energy storage",
"Non-alcoholic fatty liver disease",
"Membrane stabilizer",
"Energy source",
"Diabetic heart disease",
"food additive",
"Nutritional supplement",
"Aging",
"Emulsifier",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Smooth",
"surfactant"
] |
The molecule is both a 5lipoxygenase inhibitor and a lipoxygenase inhibitor. | Cc1cc(C(C)N(O)C(N)=O)c(C)o1 | [
"5lipoxygenase inhibitor",
"lipoxygenase inhibitor"
] |
The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts barth syndrome, aging, and tangier disease. The molecule is a apoptosis, proton trap for oxidative phosphorylation, cholesterol translocation that impacts non-alcoholic fatty liver disease and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Barth syndrome",
"Aging",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Cholesterol translocation"
] |
The molecule is a kinase modulator. | C=C(C)C(=NCc1ccc2ncccc2c1)NC(=CC)c1ccc2c(c1)C2=C | [
"kinase modulator"
] |
The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts tangier disease, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure, cholesterol translocation, stabilizing cytochrome oxidase that impacts aging and diabetic heart disease. | CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC(C)C | [
"Tangier disease",
"Barth syndrome",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Aging",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase"
] |
The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts aging, diabetic heart disease, and tangier disease. The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, cholesterol translocation that impacts barth syndrome and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Aging",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation"
] |
It has an effect on colorectal cancer, and impacts stomach cancer, breast cancer, and cardiovascular disease. It impacts seizure, alzheimer's disease, diabetes mellitus, and parkinson's disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(=O)(O)O)C1O)OC(=O)CCC[C@@H](O)[C@H](O)/C=C\C=C/C=C/C=C/[C@@H](O)C/C=C\CC | [
"Stomach cancer",
"Breast cancer",
"Colorectal cancer",
"Cardiovascular disease",
"Seizure",
"Alzheimer's Disease",
"Diabetes mellitus",
"Parkinson's disease"
] |
The molecule is a stabilizing cytochrome oxidase, a surfactant, a energy storage, and smooth. The molecule is a apoptosis, stabilizing mitochondrial structure, membrane stabilizer, emulsifier that impacts non-alcoholic fatty liver disease. The molecule is a nutritional supplement and a energy source, impacting both tangier disease and diabetic heart disease. The molecule is a food additive, proton trap for oxidative phosphorylation, cholesterol translocation that impacts aging and barth syndrome. | CCC(C)CCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)CC | [
"Stabilizing cytochrome oxidase",
"Smooth",
"surfactant",
"Energy storage",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Membrane stabilizer",
"Emulsifier",
"Nutritional supplement",
"Energy source",
"Tangier disease",
"Diabetic heart disease",
"food additive",
"Proton trap for oxidative phosphorylation",
"Aging",
"Barth syndrome",
"Cholesterol translocation"
] |
The molecule is a nutrient, energy source, emulsifier, energy storage, surfactant, membrane stabilizer. | O=C(OCCc1ccccc1)c1ccccc1O | [
"nutrient",
"Energy source",
"Emulsifier",
"Energy storage",
"surfactant",
"Membrane stabilizer"
] |
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, apoptosis that impacts diabetic heart disease and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts barth syndrome, tangier disease, and aging. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Aging",
"Stabilizing mitochondrial structure"
] |
It belongs to the diabetes treatment class of molecules. | CC(C)(C)c1ccc(C(O)c2c(C3=NCCN3)sc3ccccc23)cc1 | [
"diabetes treatment"
] |
The molecule is a 11βhsd1 inhibitor and a obesity treatment, belonging to the metabolic syndrome treatment class of molecules. | O=C(NC1C2CC3CC1CC(F)(C3)C2)N1CCCc2ccccc21 | [
"11βhsd1 inhibitor",
"obesity treatment",
"metabolic syndrome treatment"
] |
The molecule is a anti tumor and is anti biotic. | Cn1cc(NC(=O)OC(C)(C)C)nc1C(=O)Nc1ccc(-c2nc3ccc([N+](=O)[O-])cc3[nH]2)cc1 | [
"anti biotic",
"anti tumor"
] |
The molecule is a anti biotic. | CC(=O)C(C(=O)[O-])C(C)(C)C.[Na+] | [
"anti biotic"
] |
The molecule is a stabilizing mitochondrial structure that impacts diabetic heart disease, tangier disease, and aging. The molecule is a membrane stabilizer, cholesterol translocation, energy source that impacts barth syndrome and non-alcoholic fatty liver disease. The molecule is a emulsifier, a stabilizing cytochrome oxidase, a surfactant, and smooth. The molecule is a apoptosis, proton trap for oxidative phosphorylation, food additive, nutritional supplement, energy storage. | CCC(C)CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCC(C)CC | [
"Diabetic heart disease",
"Tangier disease",
"Aging",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Membrane stabilizer",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Energy source",
"Emulsifier",
"Smooth",
"Stabilizing cytochrome oxidase",
"surfactant",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"food additive",
"Nutritional supplement",
"Energy storage"
] |
The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts aging, diabetic heart disease, and tangier disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, cholesterol translocation that impacts non-alcoholic fatty liver disease and barth syndrome. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Aging",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Barth syndrome"
] |
The molecule is a apoptosis, food additive, proton trap for oxidative phosphorylation, energy storage. The molecule is a surfactant and smooth, impacting tangier disease, aging, and barth syndrome. The molecule is a cholesterol translocation, a emulsifier, and a energy source, and it impacts non-alcoholic fatty liver disease. The molecule is a membrane stabilizer, nutritional supplement, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts diabetic heart disease. | CCC(C)CCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCC(C)C | [
"Apoptosis",
"food additive",
"Proton trap for oxidative phosphorylation",
"Energy storage",
"Tangier disease",
"Aging",
"surfactant",
"Barth syndrome",
"Smooth",
"Cholesterol translocation",
"Emulsifier",
"Energy source",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Membrane stabilizer",
"Nutritional supplement",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure"
] |
The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase that impacts aging, tangier disease, and diabetic heart disease. The molecule is a apoptosis, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Cholesterol translocation",
"Aging",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Proton trap for oxidative phosphorylation"
] |
The molecule is a membrane stabilizer, energy source, energy storage, nutrient, emulsifier, surfactant. | CC(=O)/C=C\C(C)=C\C=C/C(C)=C/C=C/C=C(C)\C=C\C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C | [
"Membrane stabilizer",
"Energy source",
"Energy storage",
"nutrient",
"Emulsifier",
"surfactant"
] |
The molecule is a apoptosis, cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts barth syndrome. The molecule is a stabilizing mitochondrial structure that impacts aging, non-alcoholic fatty liver disease, tangier disease, and diabetic heart disease. | CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC(C)C | [
"Apoptosis",
"Cholesterol translocation",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Aging",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Diabetic heart disease"
] |
The molecule is a energy source and a fat storage that impacts thyroxine treatment, atherosclerosis, pancreatitis, and cancer. The molecule is a inflammatory and nutrient, and it impacts obesity. The molecule is a energy storage and a membrane stabilizer, impacting both metabolic syndrome and cardiovascular disease. | CCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC | [
"Thyroxine treatment",
"Energy source",
"Atherosclerosis",
"Pancreatitis",
"Cancer",
"Fat storage",
"Obesity",
"inflammatory",
"nutrient",
"Energy storage",
"Metabolic syndrome",
"Membrane stabilizer",
"Cardiovascular disease"
] |
The molecule is a apoptosis, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts aging and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, tangier disease, and barth syndrome. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Aging",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Cholesterol translocation",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Barth syndrome"
] |
The molecule is a nutrient. | CCCCC/C=C\C/C=C\C/C=C\CC1OC1CCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](N)C(=O)O)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"nutrient"
] |
The molecule is a anti bacterial and is anti biotic. | CCCCc1ccc(-c2ccc(CC(=O)NCCC(=O)NC(CCCCNC(=O)OC(C)(C)C)C(=O)N(C)C3C(=O)NC(C)C(=O)NC(C(=O)OC)Cc4ccc(OC)c(c4)-c4cc3ccc4OC)cc2)cc1 | [
"anti biotic",
"anti bacterial"
] |
The molecule is organic light-emitting that impacts electron transport and has an effect on both low driving voltage and low voltage. | CCC1(C)c2cc3oc4ccccc4c3cc2-c2cccc(-c3cccc(-c4nc(-c5ccccc5)nc(-c5ccccc5)n4)c3)c21 | [
"electron transport",
"low driving voltage",
"low voltage",
"organic light-emitting"
] |
The molecule is both a cancer treatment and a ezh2 inhibitor. | Cc1c(C(=O)O)cc(Cl)c2c1OC(C)(C1CCN(C(=O)C3(C(F)(F)F)CC3)CC1)O2 | [
"cancer treatment",
"ezh2 inhibitor"
] |
The molecule is a nutrient and a membrane stabilizer that impacts atherosclerosis, cardiovascular disease, obesity, and thyroxine treatment. The molecule is a inflammatory that impacts both cancer and pancreatitis. The molecule is a energy storage, a fat storage, and a energy source, and it impacts metabolic syndrome. | CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC | [
"nutrient",
"Atherosclerosis",
"Cardiovascular disease",
"Obesity",
"Membrane stabilizer",
"Thyroxine treatment",
"Cancer",
"inflammatory",
"Pancreatitis",
"Energy storage",
"Fat storage",
"Metabolic syndrome",
"Energy source"
] |
The molecule is a flavoring agent, fatty, waxy, and milky. The molecule is a nutrient, creamy, dairy, oil, sweet. | COc1ccc(-c2coc3cc(O)cc(O)c3c2=O)cc1OC1OC(CO)C(O)C(O)C1O | [
"fatty",
"waxy",
"milky",
"Flavoring agent",
"creamy",
"dairy",
"oil",
"sweet",
"nutrient"
] |
The molecule is a histone deacetylase inhibitor. | CC(C)(O)CN1CCC(Nc2cccc(N)c2)CC1 | [
"histone deacetylase inhibitor"
] |
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, proton trap for oxidative phosphorylation that impacts tangier disease and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts aging, diabetic heart disease, and barth syndrome. | CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCC | [
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Aging",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Diabetic heart disease",
"Barth syndrome"
] |
It belongs to the pain treatment class of molecules. | O=C(Nc1ccc(CF)cc1)N1CCC(F)(c2ncc(C(O)CO)cc2Cl)CC1 | [
"pain treatment"
] |
The molecule is a nutrient that affects breast cancer by impacting atherosclerosis, cervical cancer, and ulcerative colitis. | CC/C=C\C/C=C\CC(O)/C=C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)COP(=O)([O-])OCC[N+](C)(C)C | [
"nutrient",
"Atherosclerosis",
"Cervical cancer",
"Ulcerative colitis",
"Breast cancer"
] |
The molecule is a thrombin inhibitor and belongs to the anti coagulant class of molecules. | CC(C)C(NC(=O)C(NC(=O)C(CCCCNC(=O)OCc1ccccc1)NC(=O)NC(CCCN=C(N)N)C(=O)O)C(C)C)C(N)=O | [
"thrombin inhibitor",
"anti coagulant"
] |
The molecule is a cholesterol translocation and a apoptosis that impacts aging, barth syndrome, and tangier disease. The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts diabetic heart disease and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Aging",
"Cholesterol translocation",
"Barth syndrome",
"Tangier disease",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease"
] |
The molecule is a protease inhibitor and belongs to the anti viral class of molecules. | O=C(CC(Cc1ccc(F)cc1)C(=O)O)c1ccc(-c2ccccc2)[nH]1 | [
"protease inhibitor",
"anti viral"
] |
The molecule is a cell adhesion inhibitor. | COc1cc(CC(=O)N2CCC(NC(=O)Nc3ccc(CC(=O)O)cc3)C2)ccc1NC(=O)Nc1ccccc1C | [
"cell adhesion inhibitor"
] |
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, apoptosis that impacts diabetic heart disease and barth syndrome. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts tangier disease, aging, and non-alcoholic fatty liver disease. | CCCCCCCC/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Cholesterol translocation",
"Apoptosis",
"Barth syndrome",
"Tangier disease",
"Aging",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation"
] |
The molecule is a stabilizing cytochrome oxidase, apoptosis, stabilizing mitochondrial structure that impacts barth syndrome and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts aging, diabetic heart disease, and tangier disease. | CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCCC | [
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Aging",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Tangier disease"
] |
The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts barth syndrome, diabetic heart disease, and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, cholesterol translocation that impacts aging and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Apoptosis",
"Barth syndrome",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Aging",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Cholesterol translocation"
] |
It belongs to the anti microbial class of molecules. | O=C(CCl)CC(=O)NC1C(=O)N2C(C(=O)O)=C(CSc3ncns3)CSC12 | [
"anti microbial"
] |
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, cholesterol translocation that impacts aging and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts barth syndrome, tangier disease, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCC | [
"Stabilizing mitochondrial structure",
"Aging",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Diabetic heart disease",
"Barth syndrome",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Non-alcoholic fatty liver disease"
] |
The molecule is a neurological treatment. | CN(CCOc1ccc(-c2ccccc2)cc1C#Cc1ccccc1)CC(=O)OC(=O)C(F)(F)F | [
"neurological treatment"
] |
The molecule is a cholesterol translocation, stabilizing mitochondrial structure, apoptosis that impacts non-alcoholic fatty liver disease and tangier disease. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts aging, diabetic heart disease, and barth syndrome. | CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC | [
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Aging",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Barth syndrome"
] |
The molecule is a flavoring agent, a nutrient, radish, turnup, and pungent. | COc1cc(C=O)cc(OC)c1Cl | [
"radish",
"turnup",
"pungent",
"Flavoring agent",
"nutrient"
] |
The molecule is a stabilizing cytochrome oxidase, apoptosis, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease and barth syndrome. The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts aging, tangier disease, and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Cholesterol translocation",
"Aging",
"Tangier disease",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation"
] |
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts tangier disease, aging, and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Aging",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Apoptosis"
] |
The molecule is a fat storage, nutrient, inflammatory that impacts pancreatitis, obesity, and cardiovascular disease. The molecule is a membrane stabilizer and energy storage, and it impacts cancer. The molecule is a energy source that impacts thyroxine treatment, atherosclerosis, and metabolic syndrome. | CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC(C)C | [
"Fat storage",
"Pancreatitis",
"nutrient",
"Obesity",
"inflammatory",
"Cardiovascular disease",
"Membrane stabilizer",
"Cancer",
"Energy storage",
"Thyroxine treatment",
"Energy source",
"Atherosclerosis",
"Metabolic syndrome"
] |
It has an effect on colorectal cancer, and impacts stomach cancer, parkinson's disease, and diabetes mellitus. It has an effect on breast cancer, and impacts cardiovascular disease, seizure, and alzheimer's disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCCCCCC(=O)OC[C@H](COP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O)OC(=O)CCCCCCCC(=O)/C=C/C=C\CCCCC | [
"Stomach cancer",
"Parkinson's disease",
"Colorectal cancer",
"Diabetes mellitus",
"Breast cancer",
"Cardiovascular disease",
"Seizure",
"Alzheimer's Disease"
] |
The molecule is a electronic device. | CC1(C)c2cc(-c3cccc4ccc5cccnc5c34)ccc2-c2ccc(-c3cccc4ccc5cccnc5c34)cc21 | [
"electronic device"
] |
The molecule is a proton trap for oxidative phosphorylation, apoptosis, cholesterol translocation that impacts barth syndrome and aging. The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts diabetic heart disease, tangier disease, and non-alcoholic fatty liver disease. | CCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)CC | [
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Apoptosis",
"Aging",
"Cholesterol translocation",
"Diabetic heart disease",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase"
] |
The molecule is a immunomodulator and pd1/pdl1 inhibitor, and it impacts cancer treatment. | Cc1c(COc2cc(OCc3cncc(C#N)c3)c(C=O)cc2Cl)cccc1-c1ccc2oc(C3CCN(C)CC3)nc2c1 | [
"immunomodulator",
"pd1/pdl1 inhibitor",
"cancer treatment"
] |
The molecule is a membrane stabilizer, a energy source, and a emulsifier, and it impacts non-alcoholic fatty liver disease. The molecule is a energy storage, a stabilizing cytochrome oxidase, and a surfactant, it impacts tangier disease and is smooth. The molecule is a cholesterol translocation that impacts diabetic heart disease, barth syndrome, and aging. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, food additive, apoptosis, nutritional supplement. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCCCCCC | [
"Membrane stabilizer",
"Energy source",
"Emulsifier",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Energy storage",
"Stabilizing cytochrome oxidase",
"surfactant",
"Smooth",
"Cholesterol translocation",
"Diabetic heart disease",
"Barth syndrome",
"Aging",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"food additive",
"Apoptosis",
"Nutritional supplement"
] |
The molecule is a cholesterol translocation that impacts aging, tangier disease, diabetic heart disease, and barth syndrome. The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, apoptosis that impacts non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCC(C)CC | [
"Aging",
"Tangier disease",
"Diabetic heart disease",
"Barth syndrome",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Non-alcoholic fatty liver disease"
] |
The molecule is a apoptosis and a stabilizing mitochondrial structure that impacts aging, tangier disease, and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts barth syndrome and diabetic heart disease. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Aging",
"Apoptosis",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease"
] |
It belongs to the anti body class of molecules. | CCc1nc2c(N)nc3cccnc3c2n1CCCCNC(=O)c1ccc(NC)cc1 | [
"anti body"
] |
It belongs to the serotonin antagonist class of molecules. | CCCNC(=O)c1ccc(-c2cc3ccccc3c(N3CCN(CC)CC3)n2)cc1.Cl | [
"serotonin antagonist"
] |
The molecule is a chemokine receptor antagonist. | CC1(C)C=Cc2cccc(CN3CCC4(CCNC4)CC3)c2O1.Cl | [
"chemokine receptor antagonist"
] |
The molecule is a nutrient. | CCCCC/C=C\C/C=C\C/C=C\CCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C=C\[C@H](O)CCCCC)COP(=O)(O)OC[C@H](N)C(=O)O | [
"nutrient"
] |
The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts tangier disease, non-alcoholic fatty liver disease, and barth syndrome. The molecule is a proton trap for oxidative phosphorylation, apoptosis, stabilizing cytochrome oxidase that impacts diabetic heart disease and aging. | CCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC | [
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Aging",
"Apoptosis",
"Stabilizing cytochrome oxidase"
] |
The molecule is a immunomodulator and is cancer treatment. | Cc1c(COc2cc(OCc3cncc(C#N)c3)c(CNCc3cnccn3)cc2Cl)cccc1-c1cccc(OCCCN2CCC(O)C2)c1C | [
"cancer treatment",
"immunomodulator"
] |
The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, cholesterol translocation that impacts tangier disease. The molecule is a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, aging, barth syndrome, and diabetic heart disease. | CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)CC | [
"Apoptosis",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Aging",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Diabetic heart disease"
] |
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, apoptosis, stabilizing mitochondrial structure that impacts tangier disease. The molecule is a stabilizing cytochrome oxidase that impacts barth syndrome, aging, non-alcoholic fatty liver disease, and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Barth syndrome",
"Aging",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease"
] |
The molecule is a thyroxine treatment, energy storage, fat storage, inflammatory that impacts pancreatitis and cancer. The molecule is a membrane stabilizer and nutrient, and it impacts obesity. The molecule is a energy source that impacts cardiovascular disease, metabolic syndrome, and atherosclerosis. | CCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C | [
"Thyroxine treatment",
"Energy storage",
"Fat storage",
"Pancreatitis",
"Cancer",
"inflammatory",
"Obesity",
"Membrane stabilizer",
"nutrient",
"Cardiovascular disease",
"Energy source",
"Metabolic syndrome",
"Atherosclerosis"
] |
The molecule is a apoptosis, a energy source, and a proton trap for oxidative phosphorylation, and it impacts non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure, emulsifier, energy storage, membrane stabilizer that impacts aging. The molecule is a cholesterol translocation, a stabilizing cytochrome oxidase, and a food additive, and it impacts tangier disease. The molecule is a surfactant and a nutritional supplement, which impacts both diabetic heart disease and barth syndrome, and is characterized as smooth. | CC(C)CCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCC(C)C | [
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Energy source",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Emulsifier",
"Energy storage",
"Membrane stabilizer",
"Aging",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"food additive",
"Smooth",
"Diabetic heart disease",
"surfactant",
"Nutritional supplement",
"Barth syndrome"
] |
The molecule is a membrane stabilizer and a energy source, it impacts barth syndrome, and is smooth. The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, cholesterol translocation that impacts tangier disease and non-alcoholic fatty liver disease. The molecule is a emulsifier and a food additive, impacting both diabetic heart disease and aging. The molecule is a stabilizing mitochondrial structure, apoptosis, energy storage, nutritional supplement, surfactant. | CC(C)CCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCC(C)C | [
"Membrane stabilizer",
"Energy source",
"Smooth",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Emulsifier",
"Diabetic heart disease",
"Aging",
"food additive",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Energy storage",
"Nutritional supplement",
"surfactant"
] |
The molecule is a nutrient, fat storage, energy storage, inflammatory that impacts cardiovascular disease and obesity. This molecule is a member of the thyroxine treatment class, known to influence cancer and affect atherosclerosis. The molecule is a energy source and a membrane stabilizer, impacting both metabolic syndrome and pancreatitis. | CCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCC | [
"nutrient",
"Cardiovascular disease",
"Obesity",
"Fat storage",
"Energy storage",
"inflammatory",
"Thyroxine treatment",
"Cancer",
"Atherosclerosis",
"Energy source",
"Metabolic syndrome",
"Pancreatitis",
"Membrane stabilizer"
] |
The molecule is a anti biotic. | NCc1ccccc1CC(=O)NC1C(=O)N2C(C(=O)O)=C(CO)CS(=O)(=O)C12 | [
"anti biotic"
] |
The molecule is a lpxc inhibitor. | CCC(O)Cc1cc(CCC(C)(C(=O)OCc2ccccc2)S(C)(=O)=O)no1 | [
"lpxc inhibitor"
] |
The molecule is a asthma treatment member of the inflammatory disease treatment class. | CCCCCCCCCCCCCCOc1cc(Cl)c(OP(=O)(O)Oc2cccc(C[n+]3csc(C)c3)c2)cc1Cl | [
"asthma treatment",
"inflammatory disease treatment"
] |
The molecule is a nutrient that impacts obesity, cardiovascular disease, pancreatitis, metabolic syndrome, and atherosclerosis. The molecule is a thyroxine treatment and fat storage with an effect on cancer. The molecule is a energy storage, membrane stabilizer, energy source, inflammatory. | CCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC | [
"nutrient",
"Obesity",
"Cardiovascular disease",
"Pancreatitis",
"Metabolic syndrome",
"Atherosclerosis",
"Thyroxine treatment",
"Fat storage",
"Cancer",
"Energy storage",
"Membrane stabilizer",
"Energy source",
"inflammatory"
] |
The molecule is a nutrient and energy storage, belonging to the thyroxine treatment class of molecules, and impacts metabolic syndrome, obesity, and pancreatitis. The molecule is a energy source and fat storage, and it impacts cancer. The molecule is a membrane stabilizer and a inflammatory, impacting both atherosclerosis and cardiovascular disease. | CCCCCCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC)COC(=O)CCCCCCCCCCCCCCCCC(C)CC | [
"Metabolic syndrome",
"nutrient",
"Thyroxine treatment",
"Obesity",
"Energy storage",
"Pancreatitis",
"Energy source",
"Cancer",
"Fat storage",
"Atherosclerosis",
"Cardiovascular disease",
"Membrane stabilizer",
"inflammatory"
] |
The molecule is a energy source, a membrane stabilizer, and a proton trap for oxidative phosphorylation, and it impacts tangier disease. The molecule is a nutritional supplement, emulsifier, apoptosis that impacts diabetic heart disease and non-alcoholic fatty liver disease. The molecule is a surfactant, a food additive, and a energy storage, and it impacts aging. The molecule is a stabilizing mitochondrial structure, a stabilizing cytochrome oxidase, and a cholesterol translocation, it impacts barth syndrome and is smooth. | CCC(C)CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C | [
"Energy source",
"Tangier disease",
"Membrane stabilizer",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Nutritional supplement",
"Emulsifier",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"surfactant",
"food additive",
"Energy storage",
"Aging",
"Smooth",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation"
] |
The molecule is thyroxine treatment and it impacts both cardiovascular disease and pancreatitis. The molecule is a fat storage and a nutrient, impacting both atherosclerosis and metabolic syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Thyroxine treatment",
"Cardiovascular disease",
"Pancreatitis",
"Fat storage",
"nutrient",
"Atherosclerosis",
"Metabolic syndrome"
] |
The molecule is a apoptosis, a nutritional supplement, and a emulsifier, and it impacts diabetic heart disease. The molecule is a energy storage, a membrane stabilizer, and a proton trap for oxidative phosphorylation, it impacts non-alcoholic fatty liver disease and is smooth. The molecule is a food additive, energy source, stabilizing mitochondrial structure, surfactant. The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts aging, tangier disease, and barth syndrome. | CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C | [
"Diabetic heart disease",
"Apoptosis",
"Nutritional supplement",
"Emulsifier",
"Non-alcoholic fatty liver disease",
"Energy storage",
"Smooth",
"Membrane stabilizer",
"Proton trap for oxidative phosphorylation",
"food additive",
"Energy source",
"Stabilizing mitochondrial structure",
"surfactant",
"Aging",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Barth syndrome",
"Cholesterol translocation"
] |
It belongs to both the organic electroluminescent device and electroluminescent classes of molecules. | c1ccc(N(c2cc3c4ccccc4oc3c3ccccc23)c2cccc3c2oc2c(C4CCCCC4)cccc23)cc1 | [
"organic electroluminescent device",
"electroluminescent"
] |
The molecule is a food additive and a cholesterol translocation, it impacts aging, and is smooth. The molecule is a emulsifier, nutritional supplement, apoptosis that impacts tangier disease and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase and a membrane stabilizer, impacting both non-alcoholic fatty liver disease and barth syndrome. The molecule is a energy storage, proton trap for oxidative phosphorylation, surfactant, stabilizing mitochondrial structure, energy source. | CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C | [
"Smooth",
"food additive",
"Cholesterol translocation",
"Aging",
"Emulsifier",
"Nutritional supplement",
"Tangier disease",
"Diabetic heart disease",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Membrane stabilizer",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Energy storage",
"Proton trap for oxidative phosphorylation",
"surfactant",
"Stabilizing mitochondrial structure",
"Energy source"
] |
The molecule is a irritant, a food and nutrition, fruity, sweet, and banana. The molecule is a air pollutant, bitter, fragrance, laboratory chemical, solvent. | O=C(O)C(=O)C(=O)O | [
"irritant",
"Food and nutrition",
"fruity",
"sweet",
"banana",
"Air pollutant",
"bitter",
"fragrance",
"Laboratory chemical",
"solvent"
] |
The molecule is a nutrient. | COc1ccc2c([nH]c3c(-c4c(O)c(C)cc5c4[nH]c4c(C/C=C(\C)CCC=C(C)C)c(OC)ccc45)c(O)c(C)cc32)c1C/C=C(\C)CCC=C(C)C | [
"nutrient"
] |
It impacts both cancer treatment and hepatitis b treatment. | Cc1nc2cc(Br)ccn2c(=O)c1CNCC1CCC(=O)N1 | [
"cancer treatment",
"hepatitis B treatment"
] |
It impacts metabolic syndrome, cardiovascular disease, and atherosclerosis. The molecule is a nutrient and a fat storage, impacting both pancreatitis and thyroxine treatment. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)COC(=O)CCCCCCCCCCCCC/C=C\CCCCCCCC | [
"Metabolic syndrome",
"Cardiovascular disease",
"Atherosclerosis",
"nutrient",
"Pancreatitis",
"Fat storage",
"Thyroxine treatment"
] |
The molecule is both a kinase inhibitor and a hsp90 inhibitor. | CC1CC=CCCC=CC=Cc2c(Cl)c(O)cc(O)c2C(=O)O1 | [
"kinase inhibitor",
"hsp90 inhibitor"
] |
The molecule is a anti cancer, a estrogen receptor modulator, and anti cancer agent. | Cc1cc(C(C)(C)C)ccc1C1=C(c2ccc(OC3CCN(CCCF)C3)cc2)c2ccc(N)cc2CCC1 | [
"anti cancer",
"estrogen receptor modulator",
"anti cancer agent"
] |
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure, apoptosis that impacts aging. The molecule is a proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease, tangier disease, diabetic heart disease, and barth syndrome. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Cholesterol translocation",
"Aging",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Diabetic heart disease",
"Barth syndrome"
] |
The molecule is anti tumor and anti mitotic. | O=C(O)c1c(-c2ccccc2)[nH]c2cc3c(cc2c1=O)OCO3 | [
"anti tumor",
"anti mitotic"
] |
It impacts cardiovascular disease, atherosclerosis, and pancreatitis. The molecule is a nutrient and fat storage, belonging to the thyroxine treatment class of molecules, and impacts metabolic syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC | [
"Cardiovascular disease",
"Atherosclerosis",
"Pancreatitis",
"nutrient",
"Metabolic syndrome",
"Thyroxine treatment",
"Fat storage"
] |
The molecule is a nutrient, membrane stabilizer, energy source, inflammatory that has an effect on cancer and impacts thyroxine treatment. The molecule is a fat storage and energy storage, and it impacts obesity. It impacts pancreatitis, atherosclerosis, metabolic syndrome, and cardiovascular disease. | CCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCC(C)CC | [
"Cancer",
"nutrient",
"Membrane stabilizer",
"Energy source",
"Thyroxine treatment",
"inflammatory",
"Obesity",
"Fat storage",
"Energy storage",
"Pancreatitis",
"Atherosclerosis",
"Metabolic syndrome",
"Cardiovascular disease"
] |
The molecule is a organic electroluminescent element and belongs to the electronic device class of molecules, with the characteristic of being electroluminescent. | c1cc(-c2cccc(N(c3ccc4sc5ccccc5c4c3)c3cc4ccccc4c4ccccc34)c2)cc(-c2cccc3ccccc23)c1 | [
"electronic device",
"electroluminescent",
"organic electroluminescent element"
] |
The molecule is a tyk2 inhibitor. | Cn1ccc(-c2cn(-c3cccc(F)c3F)c(=O)c3c(N)n[nH]c23)n1 | [
"tyk2 inhibitor"
] |
The molecule is a nutrient that is onion and horseradish. The molecule is garlic, pungent, sulfury, and vegetable. | O=C(/C=C/c1ccc(O)cc1)OCC1OC(OC2C(c3c(O)cc4oc(-c5ccc(O)c(O)c5)cc(=O)c4c3O)OC(CO)C(O)C2O)C(O)C(O)C1O | [
"nutrient",
"onion",
"horseradish",
"garlic",
"pungent",
"sulfury",
"vegetable"
] |
The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts aging and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation and a apoptosis that impacts barth syndrome, tangier disease, and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Proton trap for oxidative phosphorylation",
"Aging",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Tangier disease",
"Cholesterol translocation",
"Apoptosis",
"Diabetic heart disease"
] |
The molecule is a pi3 kinase inhibitor. | CN1CCN(S(=O)(=O)c2cccc(Nc3cc(-c4cnc(N)nc4)nc(N4CCOCC4)n3)c2)CC1 | [
"pi3 kinase inhibitor"
] |
The molecule is a membrane stabilizer and a energy storage that impacts obesity, atherosclerosis, thyroxine treatment, and pancreatitis. The molecule is a inflammatory and energy source, and it impacts metabolic syndrome. The molecule is a fat storage and a nutrient, with effects on cancer and impacts on cardiovascular disease. | CCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCC)OC(=O)CCCCCCC | [
"Obesity",
"Atherosclerosis",
"Membrane stabilizer",
"Energy storage",
"Thyroxine treatment",
"Pancreatitis",
"inflammatory",
"Metabolic syndrome",
"Energy source",
"Fat storage",
"nutrient",
"Cancer",
"Cardiovascular disease"
] |
The molecule is a stabilizing cytochrome oxidase, apoptosis, proton trap for oxidative phosphorylation that impacts barth syndrome and aging. The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts tangier disease, non-alcoholic fatty liver disease, and diabetic heart disease. | CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCC(C)CC | [
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Aging",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Cholesterol translocation"
] |
It impacts alzheimer's treatment. | Cc1cc(C#N)cnc1OC1CCN(C(C)c2ccc3c(n2)OCCO3)CC1 | [
"alzheimer's treatment"
] |
The molecule is a liquid crystal display device. | CCOC(=O)Cc1ccc(N)cc1N | [
"liquid crystal display device"
] |
The molecule is a energy source that impacts diabetes mellitus type 2, inflammatory bowel disease, and cardiovascular disease. It impacts celiac disease, renal cell carcinoma, heart failure, and breast cancer. | CC=CC=CCCCCCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C | [
"Diabetes mellitus type 2",
"Energy source",
"Inflammatory bowel disease",
"Cardiovascular disease",
"Celiac disease",
"Renal cell carcinoma",
"Heart failure",
"Breast cancer"
] |
It belongs to the light-emitting class of molecules. | C=C(C=CC(=CC)N(c1ccccc1)c1ccccc1)c1cccc2c1-c1cc(-c3ccccc3)ccc1C21c2ccc(-c3ccc4c(c3)sc3ccccc34)cc2-c2c(-c3ccc(N(c4ccccc4)c4ccccc4)cc3)cccc21 | [
"light-emitting"
] |
The molecule is a acat inhibitor, a atherosclerosis treatment, and anti atherosclerotic. | CCCCCCCN(CCCCCSc1nc(-c2ccccc2)c(-c2ccccc2)[nH]1)C(=O)NC | [
"anti atherosclerotic",
"acat inhibitor",
"atherosclerosis treatment"
] |
Subsets and Splits